List of medicines currently in PRIME scheme

Human medicines European public assessment report (EPAR): Absimky, ustekinumab, Date of authorisation: 12/12/2024, Revision: 4, Status: Withdrawn

Human medicines European public assessment report (EPAR): Blarcamesine Anavex, blarcamesine, Status: Opinion under re-examination

Human medicines European public assessment report (EPAR): Strimvelis, autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence, Date of authorisation: 26/05/2016, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Qtern, saxagliptin,dapagliflozin, Date of authorisation: 15/07/2016, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Xigduo, dapagliflozin,metformin, Date of authorisation: 16/01/2014, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Ebymect, dapagliflozin,metformin, Date of authorisation: 15/11/2015, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Cosentyx, secukinumab, Date of authorisation: 14/01/2015, Revision: 43, Status: Authorised

Human medicines European public assessment report (EPAR): Leflunomide ratiopharm, leflunomide, Date of authorisation: 28/11/2010, Revision: 20, Status: Authorised

Agenda - Management Board meeting: 17-18 December 2025